Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dabrafenib (GSK2118436A) 是一种 Raf 抑制剂,抑制 C-Raf 和 B-RafV600E (IC50=5/0.6 nM),具有 ATP 竞争性。Dabrafenib 具有抗肿瘤活性,可用于治疗 B-RafV600E 突变的黑色素瘤。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 541 | 现货 | ||
10 mg | ¥ 697 | 现货 | ||
25 mg | ¥ 995 | 现货 | ||
50 mg | ¥ 1,570 | 现货 | ||
100 mg | ¥ 2,459 | 现货 | ||
200 mg | ¥ 3,690 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 616 | 现货 |
产品描述 | Dabrafenib (GSK2118436A) is a Raf inhibitor that inhibits C-Raf and B-RafV600E (IC50=5/0.6 nM) and is ATP-competitive. Dabrafenib exhibits antitumor activity for the treatment of B-RafV600E-mutated melanoma. |
靶点活性 | B-Raf (V600E):0.7 nM (cell free), B-Raf:5.2 nM (cell free), C-Raf:6.3 nM (cell free) |
体外活性 |
方法:195 种肿瘤细胞用 Dabrafenib 处理 72 h,使用 CellTiter-Glo Assay 检测细胞生长。 结果:编码 BRAFV600E 的 20 个细胞系中有 16 个对 Dabrafenib 敏感 (gIC50<200 nM)。其他 5 个突变 BRAF 细胞系中的 3 个对 Dabrafenib 敏感 (gIC50<30nM),包括 WM-115(BRAFV600D) 和 YUMAC(BRAFV600K)。152 个 RAS/RAF 野生型中的133个和所有 18 个突变 RAS 细胞系对 Dabrafenib 不敏感 (gIC50>10µM)。[1] 方法:黑色素瘤细胞株 LCP(BRAFV600R)、WM266 (BRAFV600D) 和 M257 (BRAFWT) 用 Dabrafenib (3-100 nM) 处理 72 h,使用 Western Blot 检测靶点蛋白表达水平。 结果:与具有野生型 BRAF 的对照细胞相比,具有 BRAFV600D/R 突变的细胞系对磷酸化 ERK 表现出更快更强的抑制作用。[2] |
体内活性 |
方法:为检测体内抗肿瘤活性,将 Dabrafenib (3-100 mg/kg,0.5% hydroxypropylmethylcellulose+0.2% Tween 80 in pH 8.0 distilled water) 灌胃给药给携带人结直肠癌肿瘤 Colo 205 (BRAFV600E) 的 CD1 nu/nu 小鼠,每天一次,持续十四天。 结果:Dabrafenib 显示出剂量依赖性的肿瘤生长抑制作用,8 只小鼠中有 4 只在 100 mg/kg 剂量下显示出部分消退。[1] 方法:为检测体内抗肿瘤活性,将 Dabrafenib (0.1-100 mg/kg,0.5% hydroxypropylmethylcellulose+0.2% Tween 80 in pH 8.0 distilled water) 灌胃给药给携带人恶性黑色素瘤 A375P F11 (BRAFV600E) 的 CD1 nu/nu 小鼠,每天一次,持续十四天。 结果:Dabrafenib 可显著减少携带 B-RafV600E 人类黑色素瘤肿瘤的小鼠的肿瘤生长。100 mg/kg 组中,50% 的治疗动物观察到肿瘤完全消退。[3] |
细胞实验 | A375P-F11 assay: A375P cells were plated in 96-well plates by limiting dilution and single cell-derived clones were harvested and tested for sensitivity to B-Raf inhibitors. The F11 clone was selected for future studies and was named A375P-F11. Cellular pSmad Assay to Measure Anti-TGF-β Activity: Activity of compounds was tested in a mechanistic assay in HepG2 cells. Cells were seeded in 12-well plates at a density of 500,000 cells/well and allowed to adhere overnight at 37℃/5% CO2. Media (BME+10% serum) was removed and compound in serum-free media was added to the cells for 45 minutes at 37℃/5% CO2. Cells were stimulated with 1 ng/ml TGF-β for 60 minutes. Cells were lysed in buffer (25 mM Tris-HCl ph: 7.5, 2 mM EDTA, 2 mM EGTA,1% Triton X-100, 0.1 % SDS, 50 mM sodium-β-glycerophosphate, 2 mM sodium orthovanadate, 12.5 mM sodium pyrophosphate, protease and phosphatase inhibitor cocktails) for 30 minutes, scraped, collected, clarified by centrifugation and prepared for western blots in LDS/reducing reagent. Samples were resolved on 4-12% Bis-Tris gels, transferred to PVDF, and probed for total and phospho-Smad2 using antibodies. Gels were imaged using the odyssey blot scanner and quantified. Phospho:total Smad2 ratios were determined and the IC50 was defined as the concentration of compound which decreased the phospho:total ratio by 50% [1]. |
动物实验 | Cells were implanted in nude mice and grown as tumor xenografts. Dosing began when tumors achieved ~150-200mm^3 volume. GSK2118436 was administered by oral gavage at a dose volume of 0.2 mL/20 gram body weight in 0.5% hydroxypropylmethylcellulose and 0.2% Tween-80 in distilled water pH 8.0. Dosing was daily for duration stipulated. Results are reported as mean tumor volume for n=7-8 mice/group. Tumors were measured twice weekly with Vernier calipers, and tumor volume was estimated from two-dimensional measurements using a prolate ellipsoid equation (Tumor volume mm^3 = (length x width^2) x 0.5). Complete tumor regression was defined as a >93% decrease in an individual tumor volume for at least 1 week [1]. |
别名 | GSK2118436A, GSK2118436, 达拉非尼 |
化合物与蛋白结合的复合物 |
Crystal structure of hPXR in complex with dabrafenib |
分子量 | 519.56 |
分子式 | C23H20F3N5O2S2 |
CAS No. | 1195765-45-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 28 mg/mL (53.9 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9247 mL | 9.6235 mL | 19.2471 mL | 48.1176 mL |
5 mM | 0.3849 mL | 1.9247 mL | 3.8494 mL | 9.6235 mL | |
10 mM | 0.1925 mL | 0.9624 mL | 1.9247 mL | 4.8118 mL | |
20 mM | 0.0962 mL | 0.4812 mL | 0.9624 mL | 2.4059 mL | |
50 mM | 0.0385 mL | 0.1925 mL | 0.3849 mL | 0.9624 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Dabrafenib 1195765-45-7 MAPK Raf GSK-2118436 inhibit GSK2118436A GSK2118436 Raf kinases GSK 2118436 达拉非尼 Inhibitor inhibitor